Posted by Michael Wonder on 11 Mar 2022
Lynparza approved in the US as adjuvant treatment for patients with germline BRCA mutated HER2 negative high risk early breast cancer
11 March 2022 - First and only approved medicine targeting BRCA mutations in early breast cancer.
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA mutated HER2 negative high risk early breast cancer who have already been treated with chemotherapy either before or after surgery.
